摘要：Recent technologies have made it possible to efficiently identify several broadly cross-neutralizing antibodies against the hemagglutinin of influenza A virus. With these advances comes a potential new age in influenza virus vaccine development and the possibility of effective, therapeutic immunotherapy.
